Estrella Immunopharma shares surge 12.23% intraday as reduced cash burn and extended 18-month runway ease investor concerns.

Estrella Immunopharma surged 12.23% intraday after a Simply Wall St analysis highlighted a 94% reduction in its annual cash burn and a manageable 18-month cash runway as of September 2025. The report noted the company’s zero debt, $1.6 million cash reserves, and a cash burn-to-market cap ratio of 1.4%, suggesting it could easily raise funds through debt or equity. While acknowledging risks, the analysis concluded shareholders need not worry about liquidity, framing the cash burn reduction as a positive sign of operational efficiency. Other news events, including unrelated updates on Estrella Resources, a local medical clinic, and a talent show victory, held no material impact on the stock’s movement.